INVA: Innoviva, Inc. - Summary | Jitta

Innoviva, Inc.

NASDAQ:INVA

Price
$13.26
Loss Chance
43.3%
5.73JITTA SCORE
22.03%Under Jitta Line
Jitta Ranking
26 / 1,041
568 / 4,594
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (56)
Recent Business Performance (54)
Financial Strength (78)
Return to Shareholders (44)
Competitive Advantage (75)
Jitta Signs
Operating MarginExpansion
Debt LevelLow Long Term Debt
CapExVery Low
Interest Coverage RatioGood
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2015
Key Stats
Jitta Score
Jitta Line
5.73
22.03%
2.04
285.53%
2.25
348.40%
Pharmaceuticals
5.17
1.53%
3.62
10.42%
4.51
44.38%
COMPANY DESCRIPTION
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.